Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension

References

• International Diabetes Federation. Diabetes Atlas, 4th edn. IDF 2009. Available at: www.diabetesatlas.org/content/powerpoint-presentation [Last accessed 26 January 2010]
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2007. Diabetes Care 2010;33(Suppl 1):S1-S99
   PubMedGoogle Scholar
• Treatment guide for diabetes. Tokyo, Japan: Japanese Diabetes Society, 2007
   Google Scholar
• Rydén L, Standl E, Bartnik M, for the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Yamazaki K, Hirao K, on behalf of the Japan Diabetes Clinical Data Management Study Group. The status of diabetes control and antidiabetic drug therapy in Japan – a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM1). Diabetes Res Clin Pract 2006;73:198-204
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group: UK prospective diabetes study 16. Overview of 6 years’ therapy of type 2 diabetes: a progressive disease. Diabetes 1995;44:1249-58
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirements for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
   PubMed Web of Science ®Google Scholar
• Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagon-like peptide-1 secretion in Japanese: comparison of type 2 diabetes mellitus and healthy controls. J Diab Invest 2010;1:56-9
   PubMed Web of Science ®Google Scholar
• Lee S, Yabe D, Nohtomi K, et al. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J 2010;57:119-26
   PubMed Web of Science ®Google Scholar
• Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011;54:10-18
   PubMed Web of Science ®Google Scholar
• Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 2010;1:8-23
   PubMed Web of Science ®Google Scholar
• Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab 2009;23:425-32
   PubMed Web of Science ®Google Scholar
• Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 2009;10:503-12
   PubMed Web of Science ®Google Scholar
• Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Prac 2004;66S:S37-S43
   Google Scholar
• Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross sectional trial of Japanese type 2 diabetes. Metabolism 2004;53:831-35
   PubMed Web of Science ®Google Scholar
• Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-4 inhibitors. Diabetes 2004;53:1326-35
   PubMed Web of Science ®Google Scholar
• Narita T, Katsuura Y, Sato T, et al. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diab Med 2009;26:187-93
   PubMed Web of Science ®Google Scholar
• Seino Y, Nanjo K, Tajima N et al. The committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diab Invest 2010;1:212-28
   Google Scholar
• Seino Y, Nanjo K, Tajima N, et al. The committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetology Int 2010;1:2-20
   Google Scholar
• Christopher RC, Fleck P, Covington P, et al. Efficacy and safety of alogliptin monotherapy over 12 weeks in patients with type 2 diabetes. Diabetes 2008;57(Suppl 1):A143
   Google Scholar
• Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab 2010;12:224-33
   PubMed Web of Science ®Google Scholar